全关节置换术后阿片类药物初治患者围手术期安全阿片处方量以降低新发持续使用风险
该回顾性队列研究纳入2018至2019年商业理赔数据库中的22,310例阿片类药物初治初次全关节置换患者,分析围手术期阿片暴露(术前1月至术后2周吗啡毫克当量)与新发持续使用(术后90至180天至少一次阿片处方)的关系,发现剂量依赖性关联,作者推荐围手术期处方<600 MME以降低风险。
要点
- 22,310例阿片初治全关节置换患者中,8.1%出现新发持续使用。
- 围手术期600-900 MME者新发持续使用风险升高77%(OR 1.77,95%CI 1.44-2.17)。
- 围手术期≥1,200 MME者风险升高285%(OR 3.85,95%CI 3.13-4.74)。
核心结论
- 围手术期吗啡毫克当量与全关节置换后阿片初治患者新发持续使用风险呈剂量依赖性关联。
- 作者推荐围手术期处方<600 MME(相当于80片5 mg羟考酮)以降低新发持续使用风险。
研究设计与样本
- 回顾性队列研究,纳入2018至2019年商业理赔数据库中22,310例接受初次全关节置换的阿片类药物初治患者。
- 围手术期阿片暴露定义为术前1个月至术后2周内阿片处方总量(吗啡毫克当量,MME)。
- 新发持续使用定义为术后90至180天至少一次阿片处方。
- 采用多变量回归分析围手术期剂量组与新发持续使用的关系。
- 证据等级为Level III。
主要发现
- 总队列中8.1%出现新发持续使用。
- 与围手术期<300 MME者相比,600-900 MME者新发持续使用风险升高77%(OR 1.77,95%CI 1.44-2.17)。
- 与围手术期<300 MME者相比,≥1,200 MME者新发持续使用风险升高285%(OR 3.85,95%CI 3.13-4.74)。
关键数值与推荐
- 围手术期阿片暴露分组阈值:<300 MME、600-900 MME、≥1,200 MME。
- 新发持续使用定义:术后90至180天至少一次阿片处方。
- 作者推荐围手术期处方<600 MME(相当于80片5 mg羟考酮)。
临床怎么用
- 作者推荐在全关节置换围手术期处方<600 MME(相当于80片5 mg羟考酮)以降低阿片初治患者新发持续使用风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Higher initial opioid dosing increases the risk of prolonged opioid use following total joint arthroplasty (TJA), and the safe amounts to prescribe are unknown. We examined the relationship between perioperative opioid exposure and new persistent usage among opioid-naïve patients after total knee and hip arthroplasty. METHODS: In this retrospective cohort study, 22,310 opioid-naïve patients undergoing primary TJA between 2018 and 2019 were identified within a commercial claims database. Perioperative opioid exposure was defined as total dose of opioid prescription in morphine milligram equivalents (MME) between 1 month prior to and 2 weeks after TJA. New persistent usage was defined as at least one opioid prescription between 90 and 180 days postoperatively. Multivariate regression analyses were performed to examine the relationship between the perioperative dosage group and the development of new persistent usage. RESULTS: For the total patient cohort, 8.1% developed new persistent usage. Compared to patients who received <300 MME, patients who received 600-900 MME perioperatively had a 77% increased risk of developing new persistent usage (odds ratio 1.77, 95% CI, 1.44-2.17), and patients who received ≥1,200 MME perioperatively had a 285% increased risk (odds ratio 3.85, 95% CI, 3.13-4.74). CONCLUSION: We found a dose-dependent association between perioperative MME and the risk of developing new persistent usage among opioid-naïve patients following TJA. We recommend prescribing <600 MME (equivalent to 80 pills of 5 mg oxycodone) during the perioperative period to reduce the risk of new persistent usage. LEVEL OF EVIDENCE: Level III.
引用
- Lan YT, Pagani NR, Chen YW, et al. A Safe Number of Perioperative Opioids to Reduce the Risk of New Persistent Usage Among Opioid-Naïve Patients Following Total Joint Arthroplasty. J Arthroplasty. 2022. PMID: 35987496. doi:10.1016/j.arth.2022.08.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。